An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
Doane, A S, Danso, M, Lal, P, Donaton, M, Zhang, L, Hudis, C, Gerald, W L
Published in Oncogene (29.06.2006)
Published in Oncogene (29.06.2006)
Get full text
Journal Article
Safety data from a phase II trial of weekly nab-paclltaxel In combination with bevacizumab as first-line treatment In metastatlc breast cancer
Danso, M, Blum, J, Robert, N, Krekow, L, Rotche, R, Smith, D, Richards, P, Anderson, T, Richards, D, O'Shaughnessy, J
Published in European journal of cancer supplements (2008)
Published in European journal of cancer supplements (2008)
Get full text
Journal Article
LBA22 - Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial
O’Shaughnessy, J., Wright, G.S., Thummala, A., Danso, M., Popovic, L.S., Pluard, T., Han, H.S., Vojnovic, Z., Vasev, N., Ma, L., Richards, D.A., Wilks, S., Milenkovic, D.M., Sorrentino, J.A., Yang, Z., Horton, J.K., Tan, A.R.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial
O’Shaughnessy, J., Wright, G.S., Thummala, A., Danso, M., Popovic, L.S., Pluard, T., Han, H.S., Vojnovic, Z., Vasev, N., Ma, L., Richards, D.A., Wilks, S., Milenkovic, D.M., Sorrentino, J.A., Yang, Z., Horton, J.K., Tan, A.R.
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Abstract PD1-09: Phase 2 safety and efficacy results of TAK-228 in combination with exemestane or fulvestrant in postmenopausal women with ER-positive/HER2-negative metastatic breast cancer previously treated with everolimus
Diamond, JR, Potter, D, Salkeni, M, Silverman, P, Haddad, T, Forget, F, Awada, A, Canon, J-L, Danso, M, Lortholary, A, Bourgeois, H, Tan-Chiu, E, Patel, C, Neuwirth, R, Leonard, EJ, Lim, B
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Published in Cancer research (Chicago, Ill.) (15.02.2019)
Get full text
Journal Article
LBA22Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GC) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized phase II trial
O’Shaughnessy, J, Wright, G S, Thummala, A, Danso, M, Popovic, L S, Pluard, T, Han, H S, Vojnovic, Z, Vasev, N, Ma, L, Richards, D A, Wilks, S, Milenkovic, D M, Sorrentino, J A, Yang, Z, Horton, J K, Tan, A R
Published in Annals of oncology (01.10.2019)
Published in Annals of oncology (01.10.2019)
Get full text
Journal Article
Abstract P2-08-04: Phase 1/2 study of oral seviteronel (VT-464), a dual CYP17-lyase inhibitor and androgen receptor (AR) antagonist, in patients with advanced AR positive triple negative (TNBC) or estrogen receptor (ER) positive breast cancer (BC)
Gucalp, A, Bardia, A, Gabrail, N, DaCosta, N, Danso, M, Elias, AD, Ali, H, Lemon, SJ, Riley, EC, Eisner, JR, Fleming, RA, Kurman, MR, Moore, WR, Traina, TA
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract OT3-04-01: BRE12-158: A phase II randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer (TNBC)
Schneider, B, Miller, KD, Badve, S, O'Neil, B, Helft, P, Chitambar, C, Falkson, C, Nanda, R, McCormick, M, Danso, M, Blaya, M, Langdon, R, Lippman, M, Paplomata, E, Walling, R, Thompson, M, Robin, E, Aggarwal, L, Shalaby, I, Canfield, V, Adesunloye, B, Lee, T, Daily, K, Ma, C, Erban, J, Radhakrishnan, N, Bruetman, D, Graham, M, Reddy, NA, Lynce, FC, Radovich, M
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction?
Miller, K, Krop, I, Schwartzberg, L, Abramson, V, Garcia-Estevez, L, Eakle, J, Nanda, R, Yardley, D, Ademuyiwa, F, Chan, S, Crown, J, Danso, M, Gelmon, K, Ma, L, Martinez-Janez, N, Gradishar, W, Steinberg, J, Tudor, IC, Uppal, H, Paton, VE, Parker, J, Hudis, CA, Traina, TA
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Published in Cancer research (Chicago, Ill.) (15.02.2016)
Get full text
Journal Article
KEYNOTE-522: Neoadjuvant Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy Followed by Adjuvant Pembrolizumab vs Placebo for Early-stage Triple Negative Breast Cancer
McArthur, H, Cortes, J, Dent, R, Pusztai, L, Kummel, S, Bergh, J, Denkert, C, Park, YH, Hui, R, Harbeck, N, Takahashi, M, Untch, M, Fasching, PA, Cardoso, F, Andersen, J, Patt, D, Danso, M, Ferreira, M, Mouret-Reynier, MA, Im, SA, Ahn, JH, Gion, M, Baron-Hay, S, Boileau, JF, Zhu, YL, Pan, W, Tryfonidis, K, Karantza, V, O'Shaughnessy, J, Schmid, P
Published in ANNALS OF SURGICAL ONCOLOGY (2022)
Get full text
Published in ANNALS OF SURGICAL ONCOLOGY (2022)
Conference Proceeding
Neoadjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy, followed by adjuvant pembrolizumab versus placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses from KEYNOTE-522
Schmid, P, Cortes, J, Dent, R, Pusztai, L, McArthur, H, Kummel, S, Bergh, J, Denkert, C, Park, YH, Hui, RN, Harbeck, N, Takahashi, M, Untch, M, Fasching, PA, Cardoso, F, Andersen, J, Patt, D, Danso, M, Ferreira, M, Mouret-Reynier, MA, Im, SA, Ahn, JH, Gion, M, Baron-Hay, S, Boileau, JF, Zhu, YL, Pan, W, Tryfonidis, K, Karantza, V, O'Shaughnessy, J
Published in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Get full text
Published in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)
Conference Proceeding
OT1-02-02: HALT MBC: HER2 Suppression with the Addition of Lapatinib to Trastuzumab in HER2−Positive Metastatic Breast Cancer (LPT112515)
Lin, N, Danso, M, David, A, Muscato, J, Ellis, C, DeSilvio, M, Garofalo, A, Nagarwala, Y, Winer, E
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Get full text
Journal Article
HER2 suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LPT112515)
Lin, N. U., Danso, M. A., David, A. K., Muscato, J. J., Ellis, C. E., Lahiri, S., Sessa, T., Nagarwala, Y. M., Winer, E.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy
Holmes, F. A., Nagarwala, Y. M., Espina, V. A., Liotta, L. A., Danso, M. A., Gallagher, R. I., McIntyre, K., Osborne, C. R. C., Mahoney, J. M., Florance, A. M., Anderson, T. C., O'Shaughnessy, J.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC)
O'Shaughnessy, J., Schwartzberg, L. S., Danso, M. A., Rugo, H. S., Miller, K., Yardley, D. A., Carlson, R. W., Finn, R. S., Charpentier, E., Freese, M., Gupta, S., Blackwood-Chirchir, A., Winer, E. P.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article
P5-13-03: Correlation of Clinical and Molecular Findings with Pathologic Response to Preoperative Lapatinib and Trastuzumab, Separately or in Combination, Prior to Neoadjuvant Chemotherapy for HER2 Positive Breast Cancer
Holmes, FA, Espina, V, Liotta, LA, Chang, JC, Nagarwala, YX, Danso, M, McIntyre, K, Osborne, CR, Krekow, LK, Gagnon, RC, Mahoney, JM, O'Shaughnessy, JA
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Published in Cancer research (Chicago, Ill.) (15.12.2011)
Get full text
Journal Article
Phase II trial of weekly nab- paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer
Danso, M. A., Blum, J. L., Robert, N. J., Krekow, L., Rotche, R., Smith, D. A., Richards, P., Anderson, T., Richards, D. A., O'Shaughnessy, J.
Published in Journal of clinical oncology (20.05.2008)
Published in Journal of clinical oncology (20.05.2008)
Get full text
Journal Article
Distinct PIK3CA mutation profiles in estrogen receptor (ER) negative breast cancer (BC) subsets
Doane, A. S., Danso, M., Lal, P., Donaton, M., Wheler, J., Moynahan, M., Zhang, L., Hudis, C., Gerald, W.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Phase II study of weekly nanoparticle paclitaxel (ABI-007), carboplatin and trastuzumab as first-line therapy of HER2-positive metastatic breast cancer
Seidman, A. D., Danso, M., Bach, A., Smith, M., Liu, M., Dickler, M., Robson, M., Moynahan, M. E., Lake, D., Hudis, C. A.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article